Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.

NCT04218656 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT04218656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04218656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.
Lead sponsor
Radboud University Medical Center
Phase
Phase 4
Overall status
Completed
Start date
June 8, 2020
Completion date
December 31, 2021
Enrollment
159 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral artery disease